Back to Search
Start Over
Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care:characteristics and predictors
- Source :
- Terslev , L , Ostergaard , M , Georgiadis , S , Brahe , C H , Ellegaard , K , Dohn , U M , Fana , V , Møller , T , Juul , L , Huynh , T K , Krabbe , S , Ornbjerg , L M , Glinatsi , D , Røgind , H , Hansen , A , Nørregaard , J , Jacobsen , S , Jensen , D V , Manilo , N , Asmussen , K , Boesen , M , Rastiemadabadi , Z , Morsel-Carlsen , L , Møller , J M , Krogh , N S & Hetland , M L 2022 , ' Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care : characteristics and predictors ' , RMD Open , vol. 8 , no. 2 .
- Publication Year :
- 2022
-
Abstract
- OBJECTIVE: To identify predictors of flare in a 2-year follow-up study of patients with rheumatoid arthritis (RA) in sustained clinical remission tapering towards withdrawal of biological disease-modifying anti-rheumatic drugs (bDMARDs). METHODS: Sustained clinical remission was defined as Disease Activity Score for 28 joints (DAS28)-C reactive protein (CRP) ≤2.6 without radiographic progression for >1 year. bDMARDs were tapered according to a mandatory clinical guideline to two-thirds of standard dose at baseline, half of dose at week 16 and discontinuation at week 32. Prospective assessments for 2 years included clinical evaluation, conventional radiography, ultrasound and MRI for signs of inflammation and bone changes. Flare was defined as DAS28-CRP ≥2.6 with ∆DAS28-CRP ≥1.2 from baseline. Baseline predictors of flare were assessed by logistic regression analyses. RESULTS: Of 142 included patients, 121 (85%) flared during follow-up of which 86% regained remission within 24 weeks after flare. Patients that flared were more often rheumatoid factor positive, had tried more bDMARDs and had higher baseline ultrasound synovitis sum scores than those not flaring. For patients on standard dose, predictors of flare within 16 weeks after reduction to two-thirds of standard dose were baseline MRI-osteitis (OR 1.16; 95% CI 1.03 to 1.33; p=0.014), gender (female) (OR 6.71; 95% CI 1.68 to 46.12; p=0.005) and disease duration (OR 1.06; 95% CI 1.01 to 1.11; p=0.020). Baseline predictors for flare within 2 years were ultrasound grey scale synovitis sum score (OR 1.19; 95% CI 1.02 to 1.44; p=0.020) and number of previous bDMARDs (OR 4.07; 95% CI 1.35 to 24.72; p=0.007). CONCLUSION: The majority of real-world patients with RA tapering bDMARDs flared during tapering, with the majority regaining remission after stepwise dose increase. Demographic and imaging parameters (MR-osteitis/ultrasound greyscale synovitis) were independent predictors of immediate flare and flare overall
Details
- Database :
- OAIster
- Journal :
- Terslev , L , Ostergaard , M , Georgiadis , S , Brahe , C H , Ellegaard , K , Dohn , U M , Fana , V , Møller , T , Juul , L , Huynh , T K , Krabbe , S , Ornbjerg , L M , Glinatsi , D , Røgind , H , Hansen , A , Nørregaard , J , Jacobsen , S , Jensen , D V , Manilo , N , Asmussen , K , Boesen , M , Rastiemadabadi , Z , Morsel-Carlsen , L , Møller , J M , Krogh , N S & Hetland , M L 2022 , ' Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care : characteristics and predictors ' , RMD Open , vol. 8 , no. 2 .
- Notes :
- application/pdf, English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1382518664
- Document Type :
- Electronic Resource